210 related articles for article (PubMed ID: 37286303)
21. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
de Castro G; Rizvi NA; Schmid P; Syrigos K; Martin C; Yamamoto N; Cheng Y; Moiseyenko V; Summers Y; Vynnychenko I; Lee SY; Bryl M; Zer A; Erman M; Timcheva C; Raja R; Naicker K; Scheuring U; Walker J; Mann H; Chand V; Mok T;
J Thorac Oncol; 2023 Jan; 18(1):106-119. PubMed ID: 36240972
[TBL] [Abstract][Full Text] [Related]
22. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
Calabrò L; Morra A; Giannarelli D; Amato G; D'Incecco A; Covre A; Lewis A; Rebelatto MC; Danielli R; Altomonte M; Di Giacomo AM; Maio M
Lancet Respir Med; 2018 Jun; 6(6):451-460. PubMed ID: 29773326
[TBL] [Abstract][Full Text] [Related]
23. Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
Petzold A; Steeb T; Wessely A; Koch EAT; Vera J; Berking C; Heppt MV
Cancer Treat Rev; 2023 Apr; 115():102543. PubMed ID: 36931146
[TBL] [Abstract][Full Text] [Related]
24. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Johnson ML; Cho BC; Luft A; Alatorre-Alexander J; Geater SL; Laktionov K; Kim SW; Ursol G; Hussein M; Lim FL; Yang CT; Araujo LH; Saito H; Reinmuth N; Shi X; Poole L; Peters S; Garon EB; Mok T;
J Clin Oncol; 2023 Feb; 41(6):1213-1227. PubMed ID: 36327426
[TBL] [Abstract][Full Text] [Related]
25. A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Ribrag V; Lee ST; Rizzieri D; Dyer MJS; Fayad L; Kurzrock R; Andritsos L; Bouabdallah R; Hayat A; Bacon L; Jiang Y; Miah K; Delafont B; Hamid O; Anyanwu S; Martinez P; Hess B
Clin Lymphoma Myeloma Leuk; 2021 May; 21(5):309-317.e3. PubMed ID: 33632668
[TBL] [Abstract][Full Text] [Related]
26. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.
Piulats JM; Watkins C; Costa-García M; Del Carpio L; Piperno-Neumann S; Rutkowski P; Hassel JC; Espinosa E; de la Cruz-Merino L; Ochsenreither S; Shoushtari AN; Orloff M; Salama AKS; Goodall HM; Baurain JF; Nathan P
Ann Oncol; 2024 Mar; 35(3):317-326. PubMed ID: 38048850
[TBL] [Abstract][Full Text] [Related]
27. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S;
N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229
[TBL] [Abstract][Full Text] [Related]
28. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer.
Doki Y; Ueno M; Hsu CH; Oh DY; Park K; Yamamoto N; Ioka T; Hara H; Hayama M; Nii M; Komuro K; Sugimoto M; Tahara M
Cancer Med; 2022 Jul; 11(13):2550-2560. PubMed ID: 35611499
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Leighl NB; Redman MW; Rizvi N; Hirsch FR; Mack PC; Schwartz LH; Wade JL; Irvin WJ; Reddy SC; Crawford J; Bradley JD; Stinchcombe TE; Ramalingam SS; Miao J; Minichiello K; Herbst RS; Papadimitrakopoulou VA; Kelly K; Gandara DR
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429332
[TBL] [Abstract][Full Text] [Related]
30. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P
N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955
[TBL] [Abstract][Full Text] [Related]
31. Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Seiwert TY; Wildsmith S; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Baker V; Evans B; Morsli N; Jill Walker ; Real K; L'Hernault A; Psyrri A
Cancer Immunol Immunother; 2024 Mar; 73(4):70. PubMed ID: 38430375
[TBL] [Abstract][Full Text] [Related]
32. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
33. Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Kim H; Park S; Jung HA; Lee SH; Park K; Ahn YC; Oh D; Ahn MJ
Cancer Res Treat; 2023 Oct; 55(4):1104-1112. PubMed ID: 37202212
[TBL] [Abstract][Full Text] [Related]
34. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
Boilève A; Hilmi M; Gougis P; Cohen R; Rousseau B; Blanc JF; Ben Abdelghani M; Castanié H; Dahan L; Tougeron D; Metges JP; Tournigand C; Garcia-Larnicol ML; Vernerey D; Turpin A; Neuzillet C
Eur J Cancer; 2021 Jan; 143():55-63. PubMed ID: 33279854
[TBL] [Abstract][Full Text] [Related]
35. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Kelley RK; Sangro B; Harris W; Ikeda M; Okusaka T; Kang YK; Qin S; Tai DW; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; Bendell J; Kim TY; Standifer N; He P; Makowsky M; Negro A; Kudo M; Abou-Alfa GK
J Clin Oncol; 2021 Sep; 39(27):2991-3001. PubMed ID: 34292792
[TBL] [Abstract][Full Text] [Related]
36. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Middleton MR; McAlpine C; Woodcock VK; Corrie P; Infante JR; Steven NM; Evans TRJ; Anthoney A; Shoushtari AN; Hamid O; Gupta A; Vardeu A; Leach E; Naidoo R; Stanhope S; Lewis S; Hurst J; O'Kelly I; Sznol M
Clin Cancer Res; 2020 Nov; 26(22):5869-5878. PubMed ID: 32816891
[TBL] [Abstract][Full Text] [Related]
37. Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
Bahig H; Aubin F; Stagg J; Gologan O; Ballivy O; Bissada E; Nguyen-Tan FP; Soulières D; Guertin L; Filion E; Christopoulos A; Lambert L; Tehfe M; Ayad T; Charpentier D; Jamal R; Wong P
BMC Cancer; 2019 Jan; 19(1):68. PubMed ID: 30642290
[TBL] [Abstract][Full Text] [Related]
38. Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.
Fujiwara Y; Takahashi Y; Okada M; Kishimoto T; Kondo S; Fujikawa K; Hayama M; Sugeno M; Ueda S; Komuro K; Lanasa M; Nakano T
Oncologist; 2022 Sep; 27(9):e703-e722. PubMed ID: 35671201
[TBL] [Abstract][Full Text] [Related]
39. A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.
Nehra J; Bradbury PA; Ellis PM; Laskin J; Kollmannsberger C; Hao D; Juergens RA; Goss G; Wheatley-Price P; Hotte SJ; Gelmon K; Tinker AV; Brown-Walker P; Gauthier I; Tu D; Song X; Khan A; Seymour L; Smoragiewicz M
Invest New Drugs; 2020 Oct; 38(5):1442-1447. PubMed ID: 32020438
[TBL] [Abstract][Full Text] [Related]
40. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.
Calabrò L; Rossi G; Morra A; Rosati C; Cutaia O; Daffinà MG; Altomonte M; Di Giacomo AM; Casula M; Fazio C; Palmieri G; Giannarelli D; Covre A; Maio M
Lancet Respir Med; 2021 Sep; 9(9):969-976. PubMed ID: 33844995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
